List of Excipients in Branded Drug METHADONE HYDROCLORIDE

« Back to Dashboard

Generic Drugs Containing METHADONE HYDROCLORIDE

Company	Ingredient	NDC	Excipient
Lannett Company Inc	methadone hydrochloride	0527-1926	ANHYDROUS CITRIC ACID
Lannett Company Inc	methadone hydrochloride	0527-1926	FD&C RED NO. 40
Lannett Company Inc	methadone hydrochloride	0527-1926	METHYLPARABEN
Lannett Company Inc	methadone hydrochloride	0527-1926	POLOXAMER 407
Lannett Company Inc	methadone hydrochloride	0527-1926	PROPYLENE GLYCOL
Lannett Company Inc	methadone hydrochloride	0527-1926	PROPYLPARABEN
Lannett Company Inc	methadone hydrochloride	0527-1926	SUCROSE

What are the Most Frequently-Used Excipients in METHADONE HYDROCLORIDE?

# Of NDCs	Excipient
7	ANHYDROUS CITRIC ACID
1	FD&C RED NO. 40
1	METHYLPARABEN
1	POLOXAMER 407
1	PROPYLENE GLYCOL
1	PROPYLPARABEN
6	SODIUM BENZOATE

Methadone Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: October 29, 2026

Methadone hydrochloride is a mature, Schedule II opioid with extensive generic competition and limited value in new-molecule exclusivity. Commercial opportunities center on formulation differentiation, excipient safety, abuse-deterrence, dose flexibility, supply reliability, opioid-treatment-program distribution, and international regulatory compliance. The strongest product concepts are oral liquids, concentrated solutions, dispersible tablets, and formulations designed for controlled dispensing rather than conventional immediate-release tablets.

What is the FDA status of methadone hydrochloride?

Methadone hydrochloride is FDA-approved for opioid use disorder and for severe pain when alternative treatments are inadequate. Approved products include tablets, oral solutions, concentrates, and injectable presentations, depending on the product and indication. Methadone is a Schedule II controlled substance in the United States under the Controlled Substances Act (DEA, 2024).

Methadone products do not have the same regulatory profile across indications:

Use	Principal regulatory setting	Commercial implication
Opioid use disorder	Federally regulated opioid treatment programs, with evolving take-home rules	Distribution, packaging, chain-of-custody, and dosing accuracy are central
Severe pain	Prescription opioid market	Competes with generic tablets, oral solutions, and other opioids
Hospital use	Institutional purchasing and injectable supply	Sterility, preservative choice, and supply reliability matter
Pediatric or geriatric use	Specialist prescribing	Dose flexibility and palatability create differentiation

Methadone’s long half-life, variable metabolism, respiratory-depression risk, and QT-interval prolongation risk affect formulation design and labeling. Product development must control dose uniformity and avoid excipients that introduce additional cardiac, metabolic, or medication-use risks (FDA, 2018; DailyMed, 2024a).

What patents protect methadone hydrochloride products?

Methadone hydrochloride itself is an old active pharmaceutical ingredient. Core composition-of-matter exclusivity is not commercially relevant in the United States. The current opportunity is generally outside the API molecule and may involve formulation, manufacturing, packaging, delivery, or abuse-deterrent technology.

How strong is the methadone patent estate?

The patent estate is typically weak for conventional immediate-release methadone hydrochloride tablets and oral solutions. Generic products have been marketed for decades, and FDA-approved products include multiple manufacturers and dosage forms.

Potentially protectable subject matter includes:

• Low-dose or high-concentration oral solutions
• Unit-dose, tamper-evident packaging
• Taste-masked formulations
• Alcohol-free or sugar-free liquids
• Sustained-release delivery systems
• Abuse-deterrent matrix or gel-forming systems
• Stable multidose formulations
• Ready-to-administer hospital products
• Automated dispensing or dosing interfaces
• Combination products pairing methadone with naloxone or other agents

A formulation patent must provide a meaningful technical advantage. Simple substitution of a conventional sweetener, flavor, preservative, or solvent generally faces obviousness risk unless the formulation demonstrates unexpected stability, palatability, dose uniformity, reduced extractability, or another measurable benefit.

When does methadone hydrochloride lose exclusivity?

Methadone hydrochloride has already lost conventional small-molecule exclusivity. The relevant commercial question is not loss of originator exclusivity but the remaining protection around specific marketed products.

Exclusivity category	Methadone hydrochloride status
New chemical entity exclusivity	Expired or inapplicable
Basic composition-of-matter patent	Expired
Conventional generic tablet competition	Established
Conventional oral-solution competition	Established
Formulation-specific exclusivity	Product-dependent
Method-of-use protection	Narrow and product-specific
Orphan exclusivity	Not generally applicable to standard methadone products
Biologic exclusivity	Not applicable

FDA’s Orange Book should be reviewed for the specific reference-listed drug and dosage form because listed patents and exclusivity can differ between products (FDA, 2024a). A generic applicant challenging an applicable listed patent may file a Paragraph IV certification under the Hatch-Waxman Act. For many conventional methadone products, the greater barrier is regulatory, operational, and controlled-substance compliance rather than patent enforcement.

What excipients are used in methadone hydrochloride formulations?

Common excipient classes vary by dosage form and manufacturer. Representative U.S. product labels identify excipients such as purified water, sucrose or other sweeteners, flavoring agents, colorants, preservatives, sodium chloride, and tablet binders or disintegrants. Exact composition must be taken from the current product label or approved application.

Oral tablets

Tablet excipient strategy usually addresses:

• Mechanical strength during controlled dispensing
• Rapid and consistent disintegration
• Low weight variability at small doses
• Stability under warehouse and pharmacy conditions
• Low risk of dose loss during splitting or manipulation
• Acceptable swallowing characteristics

A differentiated tablet could use a scoring system, multilayer design, or dose-flexible architecture. Any such design must preserve dose uniformity and avoid creating a product that is easier to crush, dissolve, inject, or misuse.

Oral solutions and concentrates

Liquids have a larger excipient decision set:

Excipient function	Candidate strategy	Key risk
Vehicle	Purified water, hydroalcoholic or nonalcoholic system	Solubility, safety, abuse potential
Sweetener	Sucrose, sorbitol, sucralose, acesulfame potassium	Diabetes, gastrointestinal tolerance, dental concerns
Buffer	Citrate, phosphate, acetate systems	pH-dependent stability and tolerability
Preservative	Benzoate, sorbate, parabens, or preservative-free design	Pediatric exposure, microbial control, compatibility
Flavor	Fruit, mint, or neutral masking system	Palatability and patient acceptance
Viscosity modifier	Cellulosic polymer or polyol	Pourability, dose recovery, syringe compatibility
Colorant	Clear or colored presentation	Product identification and medication-error risk
Chelator	EDTA where justified	Compatibility and regulatory burden

Methadone hydrochloride is water-soluble, so a simple aqueous system may be commercially attractive. The formulation must still address microbial preservation, multidose in-use stability, adsorption to dosing devices, container closure compatibility, and concentration-related dispensing errors.

What formulations are protected by methadone patents?

The most commercially defensible formulation patents would claim a defined composition linked to a measured performance advantage. Examples include:

1. A concentrated, preservative-free solution with demonstrated multidose microbial control through packaging and handling design.
2. A low-sugar or sugar-free liquid with acceptable taste and long-term chemical stability.
3. A formulation that reduces methadone adsorption to oral syringes or tubing.
4. A tamper-resistant liquid that limits extraction or concentration after common manipulation.
5. A pediatric or geriatric formulation with a verified dose range and improved administration accuracy.
6. A ready-to-use injectable presentation with extended in-use stability.
7. A depot or extended-release product that reduces dosing frequency under controlled clinical use.

Claims should be supported by comparative data against marketed methadone hydrochloride products. Useful datasets include assay, related substances, pH, preservative content, microbial limits, extractables and leachables, dose recovery, viscosity, syringe accuracy, and simulated misuse testing.

Which excipient opportunities have the highest commercial value?

1. Sugar-free and alcohol-free oral liquids

A sugar-free product can target patients with diabetes, dental concerns, or long-term treatment exposure. An alcohol-free product may improve suitability for certain treatment programs, pediatric settings, and patients with alcohol-use concerns. The opportunity is commercially credible only if taste and stability match established products.

2. Unit-dose packaging

Unit-dose cups, oral syringes, blistered doses, or sealed sachets can reduce diversion, dispensing errors, and inventory discrepancies. Packaging can be paired with tamper-evident seals and barcoding. The value proposition is strongest for opioid treatment programs, hospitals, correctional facilities, and home-delivery models.

3. High-concentration formulations

Concentrates reduce storage and transport volume and can support supervised dosing. The tradeoff is a narrower safety margin for measurement errors. A successful product would need a dedicated oral syringe, calibrated dosing device, clear concentration labeling, and human-factors validation.

4. Palatable formulations

Taste masking can improve adherence, particularly for adolescents, older adults, and patients receiving long-term therapy. Flavor systems should avoid excessive sweetness and should not increase the risk of accidental pediatric ingestion. A taste-masked product must not compromise dose recognition in supervised treatment settings.

5. Hospital-ready presentations

Ready-to-administer syringes, preservative-free ampules, and standardized concentrations can reduce compounding labor and medication errors. Hospitals may pay for these features when they reduce preparation time, waste, or dosing variability.

What regulatory pathway applies to new methadone formulations?

A conventional generic equivalent may proceed through an ANDA if it meets sameness requirements for the reference product, including active ingredient, dosage form, route, strength, quality, and bioequivalence requirements. A materially different formulation may require a 505(b)(2) application, particularly where the sponsor relies partly on published literature or an FDA-approved product but introduces a new dosage form, delivery system, concentration, or clinical use (FDA, 2023).

Key regulatory issues include:

• Controlled-substance registration and quota requirements
• Drug Enforcement Administration security controls
• Comparative bioavailability or bioequivalence
• Dose proportionality for altered concentrations
• Alcohol-dose dumping and food-effect assessment for extended release
• QT-interval evaluation where exposure changes
• Human-factors validation for dosing devices
• Extractables and leachables
• Preservative effectiveness
• In-use stability after opening
• Child-resistant and senior-friendly packaging
• Abuse-deterrence assessment where claimed

A sponsor should avoid implying abuse deterrence without robust laboratory and, where appropriate, clinical evidence. FDA evaluates abuse-deterrent labeling under a defined framework and does not treat a difficult-to-open package as equivalent to a manipulation-resistant dosage form (FDA, 2015).

What patent litigation affects methadone hydrochloride?

Methadone hydrochloride has a lower current litigation profile than newer opioid products. Conventional tablets and oral solutions are exposed to generic competition, and disputes are more likely to involve product-specific formulation claims, abbreviated applications, manufacturing arrangements, or controlled-substance supply issues.

How do Paragraph IV challenges apply?

A Paragraph IV certification states that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed. If a generic applicant files such a certification against a listed methadone formulation patent, the patent holder may bring an infringement action within the statutory period, potentially triggering a 30-month stay of approval under Hatch-Waxman rules. The commercial effect depends on the exact reference product and listed patent, not on methadone as a molecule (FDA, 2024b).

Are biosimilar risks relevant?

No. Methadone hydrochloride is a chemically synthesized small molecule, not a biologic. Biosimilar regulation under the Public Health Service Act does not apply. Competition arises through generic drug pathways, 505(b)(2) applications, formulation products, and procurement contracts.

How does methadone compare with competing opioid-treatment products?

Product category	Excipient opportunity	Market constraint
Methadone oral solution	Dose accuracy, taste, packaging, concentration control	Diversion risk and supervised-dosing rules
Buprenorphine sublingual products	Mucoadhesion, taste, film technology	Established branded and generic competition
Extended-release naltrexone	Depot suspension and injection stability	Different mechanism and patient-selection limits
Methadone tablets	Scoring, low-dose uniformity, tamper evidence	Commodity pricing
Injectable methadone	Sterility, ready-to-use packaging	Institutional market and manufacturing complexity

Methadone’s strongest competitive advantage is cost and clinical familiarity. Its main commercial weaknesses are dosing complexity, safety monitoring, diversion concerns, and limited freedom to differentiate through ordinary excipients.

What generic launch risks exist for a new methadone product?

A new entrant faces five principal risks:

1. Commodity pricing for conventional tablets and simple liquids.
2. Controlled-substance manufacturing and distribution requirements.
3. Narrow acceptable concentration and dose ranges.
4. Clinical and regulatory scrutiny of altered exposure profiles.
5. Procurement concentration among opioid-treatment programs and institutional buyers.

The best launch strategy is usually a focused product with a measurable operational benefit, such as reduced dispensing errors, lower storage burden, improved dose recovery, or simpler supervised administration. A premium price is difficult to sustain without evidence that the formulation reduces labor, waste, diversion, or adverse events.

What licensing and partnership opportunities exist?

Licensing opportunities are more likely to involve platform technologies than methadone-specific intellectual property. Relevant partners include:

• Oral-liquid formulation companies
• Controlled-substance manufacturers
• Packaging and dosing-device suppliers
• Opioid-treatment-program distributors
• Hospital injectable manufacturers
• Abuse-deterrence technology developers
• Contract development and manufacturing organizations

A license should define ownership of formulation patents, regulatory data, DEA registrations, manufacturing know-how, device rights, and territorial distribution rights. Geographic expansion may require separate assessments of controlled-drug scheduling, take-home rules, language requirements, and excipient acceptability.

What is the commercial outlook for methadone hydrochloride excipients?

The addressable opportunity is an improved product platform, not a new methadone API market. Revenue potential is greatest where excipients enable a differentiated product with one of four outcomes:

• Lower total treatment-program operating cost
• Fewer dosing and dispensing errors
• Better adherence or acceptability
• Lower diversion and manipulation risk

The base product remains vulnerable to generic price competition. A formulation company should prioritize high-value settings, including opioid-treatment programs, hospitals, correctional health systems, and specialty pharmacies. Conventional retail tablets offer the lowest differentiation potential.

Key Takeaways

• Methadone hydrochloride has no meaningful remaining composition-of-matter exclusivity.
• The commercial opportunity lies in formulation, packaging, dosing devices, and controlled-distribution systems.
• Sugar-free, alcohol-free, preservative-controlled, and unit-dose liquids are credible product concepts.
• High-concentration products can reduce logistics burden but increase medication-error risk.
• A materially different formulation may require a 505(b)(2) application rather than an ANDA.
• Paragraph IV risk depends on the specific Orange Book-listed reference product and formulation patents.
• Biosimilar competition is irrelevant because methadone is a small-molecule drug.
• Patent strength will depend on demonstrated technical performance, not routine excipient substitution.
• The most defensible commercial claims involve dose accuracy, stability, taste, syringe recovery, tamper resistance, or reduced operational cost.
• Controlled-substance compliance and treatment-program access may be greater barriers than patent expiry.

FAQs

Can methadone hydrochloride be reformulated with new excipients?

Yes. A reformulation can use new excipients if the formulation meets FDA quality, safety, stability, bioequivalence, and manufacturing requirements. The regulatory pathway depends on how substantially the new product differs from an approved reference product.

Is methadone hydrochloride an abuse-deterrent opioid?

Conventional methadone tablets and oral solutions should not be treated as abuse-deterrent products unless the specific FDA-approved product has an abuse-deterrence claim supported by FDA-reviewed evidence. Packaging controls alone do not establish an abuse-deterrent dosage form.

Can a sugar-free methadone solution receive market protection?

A sugar-free formulation may support formulation patent claims or regulatory differentiation if it has non-obvious composition and performance characteristics. Sugar substitution alone is unlikely to create strong protection without unexpected stability, palatability, or dose-delivery results.

Are methadone oral solutions suitable for pediatric products?

A pediatric formulation may be possible, but concentrated liquids create significant dosing and accidental-ingestion risks. A sponsor would need age-appropriate dosing, palatability data, dose-delivery controls, packaging safeguards, and a clear clinical rationale.

What is the most attractive methadone formulation opportunity?

A unit-dose, alcohol-free, sugar-free, accurately metered oral solution with validated stability and tamper-evident packaging has the strongest combination of clinical utility and commercial differentiation. Its value would be greatest in supervised opioid-treatment and institutional settings.

References

1. U.S. Drug Enforcement Administration. (2024). Drug scheduling. https://www.dea.gov/drug-information/drug-scheduling

2. U.S. Food and Drug Administration. (2015). Abuse-deterrent opioids: Evaluation and labeling guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/abuse-deterrent-opioids-evaluation-and-labeling

3. U.S. Food and Drug Administration. (2018). Methadone-associated QT interval prolongation and torsades de pointes. FDA Drug Safety Communication. https://www.fda.gov/

4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/applications-covered-section-505b2

5. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

6. U.S. Food and Drug Administration. (2024b). Paragraph IV drug product approvals. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/paragraph-iv-drug-product-approvals

7. DailyMed. (2024a). Methadone hydrochloride oral solution prescribing information. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/

8. U.S. Food and Drug Administration. (2024c). Medication-assisted treatment of opioid use disorder. https://www.fda.gov/drugs/information-drug-class/medication-assisted-treatment-mat-opioid-use-disorder